Aspassia Stamatoullas

11PUBLICATIONS
71CO-AUTHORS
Haematological tumoursLiquid biopsiesGene and molecular therapyHaematologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Apr 19, 2024
Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia.

Tony Marchand, Cédric Pastoret, Gandhi Damaj

|Nov 15, 2023
Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.

Massimo Federico, Catherine Fortpied, Yana Stepanishyna

|Jun 09, 2023
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).

Esther Natalie Oliva, Marta Riva, Pasquale Niscola

|Dec 01, 2022
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.

Raphael Itzykson, Valeria Santini, Sylvain Thepot

|Aug 17, 2022
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.

Aspasia Stamatoullas, Hervé Ghesquières, Pierre Feugier

|Jul 22, 2022
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.

Luc-Matthieu Fornecker, Julien Lazarovici, Igor Aurer

Pageof 2

Frequent Collaborators

3 joint publications

Lionel Ades

3 joint publications

Sophie Park

2 joint publications

René-Olivier Casasnovas

2 joint publications

Annibale Versari